Artelo Biosciences, Inc.

NasdaqCM ARTL

Artelo Biosciences, Inc. Free Cash Flow Yield on February 06, 2025

Artelo Biosciences, Inc. Free Cash Flow Yield is NA on February 06, 2025, a NA change year over year. Free cash flow yield compares the return from free cash flow to the market cap; higher yield suggests attractive investment.
  • Artelo Biosciences, Inc. 52-week high Free Cash Flow Yield is NA on February 06, 2025, which is NA below the current Free Cash Flow Yield.
  • Artelo Biosciences, Inc. 52-week low Free Cash Flow Yield is NA on February 06, 2025, which is NA below the current Free Cash Flow Yield.
  • Artelo Biosciences, Inc. average Free Cash Flow Yield for the last 52 weeks is NA.
Key data
Date Free Cash Flow Yield Market Value Added (MVA) Price to Book Ratio (P/B) Price to Earnings Ratio (P/E)
Market news
Loading...
SV Wall Street
NasdaqCM: ARTL

Artelo Biosciences, Inc.

CEO Mr. Gregory D. Gorgas M.B.A.
IPO Date June 21, 2019
Location United States
Headquarters 505 Lomas Santa Fe
Employees 5
Sector Healthcare
Industries
Description

Artelo Biosciences, Inc., a clinical stage biopharmaceutical company, focuses on developing and commercializing treatments to modulate the endocannabinoid system. Its product candidate pipeline includes ART27.13, a synthetic G protein-coupled receptor agonist, which is in Phase 1b/2a clinical trial for the treatment of anorexia associated with cancer; ART12.11, a synthetic cannabidiol cocrystal for the treatment of inflammatory bowel disease and post-traumatic stress disorder (PTSD); and ART26.12, a fatty acid binding protein 5 inhibitor for prostate and breast cancer treatment, as well as for treating PTSD. Artelo Biosciences, Inc. has research collaboration with Trinity College Dublin to investigate ART27.13 for the treatment of cancer cachexia. The company was formerly known as Reactive Medical, Inc. and changed its name to Artelo Biosciences, Inc. in April 2017. Artelo Biosciences, Inc. was incorporated in 2011 and is based in Solana Beach, California.

Similar companies

KTTA

Pasithea Therapeutics Corp.

USD 2.14

-21.90%

MNOV

MediciNova, Inc.

USD 1.92

0.52%

SLRX

Salarius Pharmaceuticals, Inc.

USD 2.01

-8.64%

AKTX

Akari Therapeutics, Plc

USD 1.09

-19.26%

CRIS

Curis, Inc.

USD 3.34

-4.84%

StockViz Staff

February 7, 2025

Any question? Send us an email